HLA-E: Presentation of a broader peptide repertoire impacts the cellular immune response - Implications on HSCT outcome

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Kraemer, Thomas ^a   Celik, Alexander A ^a   Huyton, Trevor ^a   Kunze Schumacher, Heike ^a   Blasczyk, Rainer ^a   Bade Döding, Christina ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA E ANTIGEN;

ARTICLE; BINDING ASSAY; CELL LINE; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; HUMAN CELL; LIGAND BINDING; MASS SPECTROMETRY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OUTCOME ASSESSMENT; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; T2E CELL;

EID: 84940416440     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/346714     Document Type: Article

References (68)

1. C. Bade-Doeding, H. A. Elsner, B. Eiz-Vesper, A. Seltsam, U. Holtkamp, and R. Blasczyk, "A single amino-acid polymorphism in pocket A of HLA-A∗6602 alters the auxiliary anchors compared with HLA-A∗6601 ligands," Immunogenetics, vol. 56, no. 2, pp. 83-88, 2004.
2. C. Bade-Doeding, T. Huyton, B. Eiz-Vesper, and R. Blasczyk, "The composition of the F pocket in HLA-A∗74 generates C-terminal promiscuity among its bound peptides," Tissue Antigens, vol. 78, no. 5, pp. 378-381, 2011.
3. ∗44:08," Immunogenetics, vol. 64, no. 3, pp. 245-249, 2012.
4. ∗44 allotypes," Haematologica, vol. 97, no. 1, pp. 98-106, 2012.
5. ∗0302 located outside the pocket F alters the PΩ peptide motif," Tissue Antigens, vol. 76, no. 6, pp. 487-490, 2010.
6. T. Huyton, N. Ladas, H. Schumacher, R. Blasczyk, and C. Bade-Doeding, "Pocketcheck: updating the HLA class I peptide specifcity roadmap," Tissue Antigens, vol. 80, no. 3, pp. 239-248, 2012.
7. ∗44:09," Immunogenetics, vol. 64, no. 9, pp. 663-668, 2012.
8. ∗41 allotypic family," Haema-tologica, vol. 96, no. 1, pp. 110-118, 2011.
9. S. J. Lee, J. Klein, M. Haagenson et al., "High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation," Blood, vol. 110, no. 13, pp. 4576-4583, 2007.
10. E. W. Petersdorf, "Risk assessment in haematopoietic stem cell transplantation: histocompatibility," Best Practice & Research: Clinical Haematology, vol. 20, no. 2, pp. 155-170, 2007.
11. ∗0103 confers protection from acute graf-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation," Transplantation, vol. 82, no. 11, pp. 1436-1440, 2006.
12. E. Hosseini, A. P. Schwarer, and M. Ghasemzadeh, "The impact of HLA-E polymorphisms in graf-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation," Iranian Journal of Allergy, Asthma and Immunology, vol. 11, no. 1, pp. 15-21, 2012.
13. G. I. Mossallam, R. A. Fattah, A. El-Haddad, and H. K. Mahmoud, "HLA-E polymorphism and clinical outcome afer allogeneic hematopoietic stem cell transplantation in Egyptian patients," Human Immunology, vol. 76, no. 2-3, pp. 161-165, 2015.
14. L. P. Felício, I. O. P. Porto, C. T. Mendes-Junior et al., "Worldwide HLA-E nucleotide and haplotype variability reveals a conserved gene for coding and 3′ untranslated regions," Tissue Antigens, vol. 83, no. 2, pp. 82-93, 2014.
15. L. C. Sullivan, C. S. Clements, J. Rossjohn, and A. G. Brooks, "The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity," Tissue Antigens, vol. 72, no. 5, pp. 415-424, 2008.
16. L. C. Sullivan, H. L. Hoare, J. McCluskey, J. Rossjohn, and A. G. Brooks, "A structural perspective on MHC class Ib molecules in adaptive immunity," Trends in Immunology, vol. 27, no. 9, pp. 413-420, 2006.
17. C. Romagnani, G. Pietra, M. Falco et al., "Identifcation of HLA-E-specifc alloreactive Thlymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11328-11333, 2002.
18. F. Borrego, M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks, "Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis," The Journal of Experimental Medicine, vol. 187, no. 5, pp. 813-818, 1998.
19. V. M. Braud, D. S. J. Allan, C. A. O'Callaghan et al., "HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C," Nature, vol. 391, no. 6669, pp. 795-799, 1998.
20. A. G. Brooks, F. Borrego, P. E. Posch et al., "Specifc recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells," The Journal of Immunology, vol. 162, no. 1, pp. 305-313, 1999.
21. N. Lee, M. Llano, M. Carretero, F. Navarro, M. López-Botet, and D. E. Geraghty, "HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 9, pp. 5199-5204, 1998.
22. J. Nattermann, H. D. Nischalke, V. Hofmeister et al., "HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells," Antiviral Terapy, vol. 10, no. 1, pp. 95-107, 2005.
23. G. Terrazzano, M. Sica, C. Gianfrani et al., "Gliadin regulates the NK-dendritic cell cross-talk by HLA-E surface stabilization," The Journal of Immunology, vol. 179, no. 1, pp. 372-381, 2007.
24. P. García, M. Llano, A. B. de Heredia et al., "Human T cell receptor-mediated recognition of HLA-E," European Journal of Immunology, vol. 32, no. 4, pp. 936-944, 2002.
25. + cytolytic T lymphocytes," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 19, pp. 10896-10901, 2003.
26. E. H. Warren, X. C. Zhang, S. Li et al., "Efect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT," Blood, vol. 120, no. 14, pp. 2796-2806, 2012.
27. D. Pende, S. Marcenaro, M. Falco et al., "Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidenti-cal HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefnition of inhibitory KIR specifcity," Blood, vol. 113, no. 13, pp. 3119-3129, 2009.
28. N. Lee, D. R. Goodlett, A. Ishitani, H. Marquardt, and D. E. Geraghty, "HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences," The Journal of Immunology, vol. 160, no. 10, pp. 4951-4960, 1998.
29. T. Kraemer, R. Blasczyk, and C. Bade-Doeding, "HLA-E: a novel player for histocompatibility," Journal of Immunology Research, vol. 2014, Article ID 352160, 7 pages, 2014.
30. J. Michaëlsson, C. T. de Matos, A. Achour, L. L. Lanier, K. Kärre, and K. Söderström, "A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition," The Journal of Experimental Medicine, vol. 196, no. 11, pp. 1403-1414, 2002.
31. S. Bauer, V. Groh, J. Wu et al., "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA," Science, vol. 285, no. 5428, pp. 727-729, 1999.
32. C. Bottino, R. Biassoni, R. Millo, L. Moretta, and A. Moretta, "The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering," Human Immunology, vol. 61, no. 1, pp. 1-6, 2000.
33. L. L. Lanier, "Up on the tightrope: natural killer cell activation and inhibition," Nature Immunology, vol. 9, no. 5, pp. 495-502, 2008.
34. D. Tortorella, B. Gewurz, D. Schust, M. Furman, and H. Ploegh, "Down-regulation of MHC class I antigen presentation by HCMV; lessons for tumor immunology," Immunological Investigations, vol. 29, no. 2, pp. 97-100, 2000.
35. P. Tomasec, V. M. Braud, C. Rickards et al., "Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40," Science, vol. 287, no. 5455, pp. 1031-1033, 2000.
36. M. Ulbrecht, S. Martinozzi, M. Grzeschik et al., "Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis," The Journal of Immunology, vol. 164, no. 10, pp. 5019-5022, 2000.
37. M. Vaĺes-Gómez, H. T. Reyburn, R. A. Erskine, M. López-Botet, and J. L. Strominger, "Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E," The EMBO Journal, vol. 18, no. 15, pp. 4250-4260, 1999.
38. + NK cell expansion," The Journal of Clinical Investigation, vol. 124, no. 12, pp. 5305-5316, 2014.
39. N. K. Björkström, T. Lindgren, M. Stoltz et al., "Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus," The Journal of Experimental Medicine, vol. 208, no. 1, pp. 13-21, 2011.
40. H. L. Hoare, L. C. Sullivan, C. S. Clements et al., "Subtle changes in peptide conformation profoundly afect recognition of the non-classical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors," Journal of Molecular Biology, vol. 377, no. 5, pp. 1297-1303, 2008.
41. E. J. Petrie, C. S. Clements, J. Lin et al., "CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence," The Journal of Experimental Medicine, vol. 205, no. 3, pp. 725-735, 2008.
42. H. Kunze-Schumacher, R. Blasczyk, and C. Bade-Doeding, "Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches," Journal of Immunology Research, vol. 2014, Article ID 246171, 8 pages, 2014.
43. H. G. Drexler and Y. Matsuo, "Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma," Leukemia, vol. 14, no. 5, pp. 777-782, 2000.
44. M. J. Robertson, K. J. Cochran, C. Cameron, J.-M. Le, R. Tantravahi, and J. Ritz, "Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia," Experimental Hematology, vol. 24, no. 3, pp. 406-415, 1996.
45. ∗44:02P," Human Immunology, vol. 72, no. 11, pp. 1039-1044, 2011.
46. M. Hirosawa, M. Hoshida, M. Ishikawa, and T. Toya, "MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming," Computer Applications in the Biosciences, vol. 9, no. 2, pp. 161-167, 1993.
47. G. G. Kim, V. S. Donnenberg, A. D. Donnenberg, W. Gooding, and T. L. Whiteside, "A novel multiparametric fow cytometry-based cytotoxicity assay simultaneously immunophenotypes efector cells: comparisons to a 4 h 51Cr-release assay," Journal of Immunological Methods, vol. 325, no. 1-2, pp. 51-66, 2007.
48. P. Emsley, B. Lohkamp, W. G. Scott, and K. Cowtan, "Features and development of Coot," Acta Crystallographica Section D: Biological Crystallography, vol. 66, part 4, pp. 486-501, 2010.
49. A. Sali and T. L. Blundell, "Comparative protein modelling by satisfaction of spatial restraints," Journal of Molecular Biology, vol. 234, no. 3, pp. 779-815, 1993.
50. S. L. Heatley, G. Pietra, J. Lin et al., "Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells," Journal of Biological Chemistry, vol. 288, no. 12, pp. 8679-8690, 2013.
51. M. Allard, P. Tonnerre, S. Nedellec et al., "HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation," PLoS ONE, vol. 7, no. 11, Article ID e50951, 2012.
52. S. L. Wooden, S. R. Kalb, R. J. Cotter, and M. J. Soloski, "Cutting edge: HLA-E binds a peptide derived from the ATP-binding cassette transporter multidrug resistance-associated protein 7 and inhibits NK cell-mediated lysis," The Journal of Immunology, vol. 175, no. 3, pp. 1383-1387, 2005.
53. B. K. Kaiser, J. C. Pizarro, J. Kerns, and R. K. Strong, "Structural basis for NKG2A/CD94 recognition of HLA-E," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 18, pp. 6696-6701, 2008.
54. V. Braud, E. Y. Jones, and A. McMichael, "The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9," European Journal of Immunology, vol. 27, no. 5, pp. 1164-1169, 1997.
55. J. Stevens, E. Joly, J. Trowsdale, and G. W. Butcher, "Peptide binding characteristics of the non-classical class Ib MHC molecule HLA-E assessed by a recombinant random peptide approach," BMC Immunology, vol. 2, article 25, 2001.
56. J. D. Miller, D. A. Weber, C. Ibegbu, J. Pohl, J. D. Altman, and P. E. Jensen, "Analysis of HLA-E peptide-binding specifcity and contact residues in bound peptide required for recognition by CD94/NKG2," Journal of Immunology, vol. 171, no. 3, pp. 1369-1375, 2003.
57. C. A. O'Callaghan, J. Tormo, B. E. Willcox et al., "Structural features impose tight peptide binding specifcity in the nonclassical MHC molecule HLA-E," Molecular Cell, vol. 1, no. 4, pp. 531-541, 1998.
58. H. L. Hoare, L. C. Sullivan, G. Pietra et al., "Structural basis for a major histocompatibility complex class Ib-restricted T cell response," Nature Immunology, vol. 7, no. 3, pp. 256-264, 2006.
59. R. K. Strong, M. A. Holmes, P. Li, L. Braun, N. Lee, and D. E. Geraghty, "HLA-E allelic variants: correlating diferential expression, peptide afnities, crystal structures, and thermal stabilities," The Journal of Biological Chemistry, vol. 278, no. 7, pp. 5082-5090, 2003.
60. M. Ulbrecht, S. Modrow, R. Srivastava, P. A. Peterson, and E. H. Weiss, "Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation," Journal of Immunology, vol. 160, no. 9, pp. 4375-4385, 1998.
61. M. H. Lampen, C. Hassan, M. Sluijter et al., "Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2," Molecular Immunology, vol. 53, no. 1-2, pp. 126-131, 2013.
62. ∗01:03/gly107 immune function," Tissue Antigens, vol. 85, no. 5, p. 326, 2015.
63. X. Chen, P. P. Trivedi, B. Ge, K. Krzewski, and J. L. Strominger, "Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 15, pp. 6329-6334, 2007.
64. P. André, R. Castriconi, M. Espeli et al., "Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors," European Journal of Immunology, vol. 34, no. 4, pp. 961-971, 2004.
65. B. K. Kaiser, F. Barahmand-Pour, W. Paulsene, S. Medley, D. E. Geraghty, and R. K. Strong, "Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping afnities and thermodynamics," The Journal of Immunology, vol. 174, no. 5, pp. 2878-2884, 2005.
66. K. J. Green, J. J. Miles, J. Tellam, W. J. M. van Zuylen, G. Connolly, and S. R. Burrows, "Potent T cell response to a class I-binding 13-mer viral epitope and the infuence of HLA micropolymorphism in controlling epitope length," European Journal of Immunology, vol. 34, no. 9, pp. 2510-2519, 2004.
67. M. Probst-Kepper, V. Stroobant, R. Kridel et al., "An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infltrating CD8 Thlymphocytes," Journal of Experimental Medicine, vol. 193, no. 10, pp. 1189-1198, 2001.
68. F. E. Tynan, N. A. Borg, J. J. Miles et al., "High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance," Journal of Biological Chemistry, vol. 280, no. 25, pp. 23900-23909, 2005.